JA
JAZZ.US Jazz Pharmaceuticals PLC
- Market cap
- USD 15.5B
- P/E
- 71.5x
- P/B
- 3.70x
- ROE
- 0.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is JAZZ.US undervalued?
Graham numberThe Graham number of Jazz Pharmaceuticals PLC cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jazz Pharmaceuticals PLC fundamental analysis
No fundamental analysis for Jazz Pharmaceuticals PLC yet.
Jazz Pharmaceuticals PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymp…
Full company profileJazz Pharmaceuticals PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jazz Pharmaceuticals PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.49B | 1.62B | 1.89B | 2.16B | 2.36B | 3.09B | 3.66B | 3.83B | 4.07B | 4.27B | 4.69B |
| Gross Profit | 1.38B | 1.51B | 1.77B | 2.03B | 2.21B | 2.65B | 3.12B | 3.40B | 3.62B | 3.76B | 3.98B |
| Operating Income | 592M | 529M | 615M | 532M | 378M | 170M | -65.5M | 579M | 717M | 224M | 64.8M |
| EBITDA | 754M | 779M | 933M | 1.01B | 1.04B | 1.03B | 1.47B | 1.45B | 1.52B | 263M | 982M |
| Net Income | 397M | 488M | 447M | 523M | 239M | -329M | -224M | 415M | 560M | -356M | 3.33M |
| EPS | 6.41 | 7.96 | 7.30 | 9.09 | 4.22 | -5.51 | -3.58 | 5.76 | 8.49 | -5.84 | 0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 4.80B | 5.12B | 5.20B | 5.54B | 6.54B | 12.3B | 10.8B | 11.4B | 12.0B | 11.7B | 12.0B |
| Total Liabilities | 2.92B | 2.41B | 2.45B | 2.43B | 2.88B | 8.33B | 7.75B | 7.66B | 7.92B | 7.34B | 7.81B |
| Shareholders' Equity | 1.88B | 2.71B | 2.76B | 3.11B | 3.66B | 3.97B | 3.09B | 3.74B | 4.09B | 4.32B | 4.19B |
| Cash & Short-term Investments | 426M | 601M | 825M | 1.08B | 2.13B | 591M | 881M | 1.63B | 2.99B | 2.44B | 2.86B |
| Total Debt | 2.03B | 1.58B | 1.60B | 1.77B | 2.25B | 6.15B | 5.81B | 5.79B | 6.16B | 5.42B | 5.65B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 591M | 693M | 799M | 776M | 900M | 779M | 1.27B | 1.09B | 1.40B | 1.36B | 1.77B |
| Capital Expenditure | 182M | 114M | 131M | 182M | 379M | 45.5M | 498M | 24.0M | 48.1M | 210M | 72.0M |
| Free Cash Flow | 409M | 579M | 667M | 594M | 520M | 733M | 774M | 1.07B | 1.35B | 1.15B | 1.70B |
| Ratios | |||||||||||
| ROE | 21.1% | 18.0% | 16.2% | 16.8% | 6.5% | -8.3% | -7.3% | 11.1% | 13.7% | -8.2% | 0.1% |
| ROA | 8.3% | 9.5% | 8.6% | 9.4% | 3.7% | -2.7% | -2.1% | 3.6% | 4.7% | -3.1% | 0.0% |
| Net Profit Margin | 26.7% | 30.1% | 23.6% | 24.2% | 10.1% | -10.6% | -6.1% | 10.8% | 13.8% | -8.3% | 0.1% |
| Debt to Equity | 1.08x | 0.58x | 0.58x | 0.57x | 0.61x | 1.55x | 1.88x | 1.55x | 1.51x | 1.26x | 1.35x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jazz Pharmaceuticals PLC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 98.0M | 1.57 | - |
| 2021 | USD 99.7M | 1.67 | - |
| 2020 | USD 99.7M | 1.76 | 41.8% |
| 2019 | USD 57.8M | 1.00 | 11.0% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Jazz Pharmaceuticals PLC
- Insiders 3.41%
- Institutions 96.59%
- Public & others 0.00%
- Shares outstanding 64.2M
- Free float 62.2M
Top funds holding JAZZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 2.33M | 3.64% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.95M | 3.04% | +3.22% | Sep 2026 |
| American Funds Fundamental Invs A | 1.90M | 2.96% | -9.52% | Sep 2026 |
| FullerThaler Behavioral Sm-Cp Eq R6 | 1.56M | 2.43% | -2.87% | Jun 2026 |
| Vanguard Small Cap Index | 1.39M | 2.16% | +1.25% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 903K | 1.41% | +3.72% | Sep 2026 |
| VictoryShares Free Cash Flow ETF | 706K | 1.10% | +0.34% | Oct 2026 |
| Invesco S&P MidCap Momentum ETF | 704K | 1.10% | -0.06% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 656K | 1.02% | +12.93% | Sep 2026 |
| Franklin DynaTech Fund A | 500K | 0.78% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 480K | 0.75% | +4.61% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 451K | 0.70% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 411K | 0.64% | +2.29% | Aug 2026 |
| Fidelity Low-Priced Stock | 400K | 0.62% | -0.06% | Aug 2026 |
| Fidelity Select Health Care | 400K | 0.62% | +53.85% | Aug 2026 |
| American Funds SMALLCAP World A | 400K | 0.62% | -20.00% | Sep 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 390K | 0.61% | -0.26% | Oct 2026 |
| JPMorgan Mid Cap Value L | 366K | 0.57% | +0.71% | Sep 2026 |
| Fidelity Balanced | 366K | 0.57% | -0.02% | Aug 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 353K | 0.55% | 0.00% | Oct 2026 |
Top institutions holding JAZZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 5.97M | 9.30% | +6.74% | Jun 2026 |
| FMR Inc | 4.61M | 7.18% | +102.54% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.04M | 4.73% | +1.78% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.73M | 4.25% | +3.07% | Jun 2026 |
| Capital World Investors | 2.70M | 4.20% | +0.91% | Jun 2026 |
| LSV Asset Management | 2.14M | 3.33% | -6.12% | Sep 2026 |
| Franklin Templeton Inc | 2.04M | 3.18% | +4.15% | Jun 2026 |
| State Street Corp | 2.00M | 3.12% | +5.72% | Jun 2026 |
| Fuller & Thaler Asset Management Inc | 1.64M | 2.55% | -2.24% | Jun 2026 |
| Bank of New York Mellon Corp | 1.58M | 2.46% | -6.04% | Jun 2026 |
| AQR Capital Management LLC | 1.52M | 2.37% | +13.76% | Jun 2026 |
| Geode Capital Management, LLC | 1.48M | 2.31% | +19.83% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.45M | 2.26% | -15.19% | Sep 2026 |
| Ameriprise Financial Inc | 1.22M | 1.89% | -24.43% | Jun 2026 |
| JPMorgan Chase & Co | 1.16M | 1.81% | -3.62% | Jun 2026 |
| Bank of America Corp | 1.14M | 1.77% | +11.95% | Jun 2026 |
| Citadel Advisors Llc | 1.01M | 1.57% | -20.07% | Jun 2026 |
| Swedbank AB | 968K | 1.51% | -2.42% | Jun 2026 |
| BNP Paribas Investment Partners SA | 799K | 1.25% | -9.70% | Jun 2026 |
| Millennium Management LLC | 764K | 1.19% | -39.50% | Jun 2026 |
Jazz Pharmaceuticals PLC company profile
- Company name
- Jazz Pharmaceuticals PLC
- Ticker
- JAZZ.US
- Exchange
- USA Stocks
- Listed since
- Jun 1, 2007
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,890
- Fiscal year end
- December
- Address
- Waterloo Exchange, Dublin, Ireland, D04 E5W7
- Phone
- 353 1 634 7800
- Website
- jazzpharma.com
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals PLC management
10- Mr. Bruce C. CozaddCo-Founder & Chairman · born 1964
- Ms. Renee D. GalaPresident, CEO & Director · born 1972
- Mr. Philip L. JohnsonExecutive VP & CFO · born 1964
- Ms. Neena M. Patil J.D.Executive VP & Chief Legal Officer · born 1975
- Dr. Robert Iannone M.D.Executive VP, Chief Medical Officer and Global Head of Research & Development · born 1967
- Ms. Samantha PearceExecutive VP & Chief Commercial Officer · born 1966
- Ms. Patricia CarrSenior VP & Chief Accounting Officer · born 1971
- Mr. John D. BluthHead of Investor Relations · born 1973
- Ms. Heidi MannaExecutive VP & Chief People Officer · born 1971
- Dr. Jed Black M.D.Senior Vice President of Sleep & CNS Medicine